AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Development of a Digital Personalised Nutrition Tool for Adolescents Undergoing Cancer Treatment

RecruitingNAAges 12 Years - 18 YearsAllKU Leuven
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study aims to develop and test MybYte, a smartphone tool designed to support personalised nutrition for teenagers aged 12-18 undergoing cancer treatment. MybYte will ask short questions about eating, appetite and treatment-related symptoms and provide personalised nutrition advice developed by healthcare professionals. In Phase 1, around 15 teenagers will help co-design and refine the tool through interviews and feedback. In Phase 2, around 15 newly diagnosed teenagers will use MybYte for one week each month over six months, alongside routine assessments of nutrition, body composition, taste, energy needs and quality of life. The study will assess whether MybYte is acceptable, practical and helpful for teenagers receiving cancer treatment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria * Written informed consent has been obtained from a parent/legal guardian. * Written assent has been obtained from participants. * Aged between 12 and 18 years at the time of enrolment. * Ability to use a smartphone independently. * Adequate cognitive capacity to participate in study procedures, as determined by the research team. * Proficiency in Dutch * For Phase 1: * Currently receiving, or having previously received cancer treatment (including chemotherapy) at University Hospitals Leuven within the specified age range. * For Phase 2: * New histological diagnosis of cancer * Enrolled into the study within 6 weeks of diagnosis. * Currently receiving cancer treatment (including chemotherapy) at University Hospitals Leuven. Exclusion Criteria Phase 1 and 2: * Presence of cognitive, developmental, or neurological impairments that compromise the ability to provide informed consent or assent, or that impair \\ independent use of a digital tool * Medical instability or clinical condition deemed too unwell for participation, as determined by the treating clinician. * Admitted to the intensive care unit during the enrollment period. * Currently on a palliative care trajectory.
๐Ÿ’Š

What it tests

  • The MybYte tool, a digital personalised nutrition tool for adolescents undergoing cancer treatment
๐Ÿ“

Where

1 site
University Hospitals Leuven (UZ Leuven)
Leuven, Belgium
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy